Ariad Pharmaceuticals (NASDAQ:ARIA), a company whose shares are moving quickly, is trading 1.7% higher to $16.60. The S&P is currently trading fractionally lower to 1,632 and the Dow Jones Industrial Average is trading fractionally lower to 15,091.
Ariad Pharmaceuticals (NASDAQ:ARIA) has potential upside of 69.8% based on a current price of $16.60 and analysts' consensus price target of $28.19. The stock should run into initial resistance at its 50-day moving average (MA) of $18.83 and subsequent resistance at its 200-day MA of $20.57.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.
In the past 52 weeks, shares of Ariad Pharmaceuticals have traded between a low of $15.13 and a high of $25.40 and are now at $16.60, which is 10% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 2.1%.